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Background: One of the main causes of mortality and morbidity following subarachnoid hemorrhage (SAH) is the
development of cerebral vasospasm, a frequent complication arising in the weeks after the initial bleeding. Despite
extensive research, no effective treatment of vasospasm exists to date. Prostacyclin is a potent vasodilator and inhibitor
of platelet aggregation. In vitro models have shown a relaxing effect of prostacyclin after induced contraction in
cerebral arteries, and a recent pilot trial showed a positive effect on cerebral vasospasm in a clinical setting. No
randomized clinical trials have investigated the possible pharmacodynamic effects of prostacyclin on the human brain
following SAH.
Methods/Design: This trial is a single centre, randomized, placebo-controlled, parallel group, double blinded, clinical
pilot trial. A total of 90 patients with SAH will be randomized to one of three intervention arms: epoprostenol at 1 ng/
kg/min, epoprostenol at 2 ng/kg/min, or placebo in addition to the standard treatment. Trial medication will start on
Day 5 after SAH and continue to Day 10. The primary outcome measure is changes in cerebral blood flow measured by
a computed tomography (CT) perfusion scan. The secondary outcomes are vasospasm measured by a CT angiography,
regional blood flow, clinical symptoms of cerebral ischemia, and outcome at three months (Glasgow Outcome Scale).
Discussion: The primary outcome has been altered slightly since the publication of our study protocol. Global cerebral
blood flow is now primary outcome, whereas regional blood flow is a secondary outcome.
Trial registration: Clinicaltrials.gov NCT01447095. Registration date: 11 October 2011.
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Subarachnoid hemorrhage (SAH) accounts for only 5% of
strokes but the loss of productive life years due to SAH
approaches that for ischaemic stroke and intracerebral
haemorrhage [1]. Delayed ischaemic neurological deficit
(DIND) is one of the main causes of mortality and mor-
bidity following SAH [2]. Although challenged lately, cere-
bral vasospasm is still regarded as an important factor in
the cause of DIND. Despite extensive research, there is* Correspondence: rune333@gmail.com
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Prostacyclin is an endogenous substance released from
the vascular endothelium. It is a potent vasodilator and in-
hibitor of leukocyte activation, platelet aggregation, and
leukocyte-endothelial interactions, which are all potential
agents against ischemic event [3]. To date, no randomized
clinical trials have investigated the possible effects of pros-
tacyclin on the human brain following SAH.Methods/Design
This trial is a single centre, randomized, placebo con-
trolled, parallel group, double blindedclinical trial con-
ducted at the Neurointensive Care Unit, of Copenhagentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ethics committee on human research (reference number
H-1-2011-087) and the Danish Medicines Agency (EudraCT
2011-002798–5), and will be carried out in compliance
with the Declaration of Helsinki. The trial will be re-
ported in compliance with the CONSORT statement A
total of 90 patients will be randomized to one of three
intervention arms after informed consent is obtained
(see flowchart in Figure 1). No interim analysis will
take place. Protocol details are published in the journal
Trials [4].Objective
This trial is an explorative pilot trial designed to investi-
gate the feasibility and possible effects of low-dose pros-
tacyclin on the primary outcome of changes in cerebral
blood flow (CBF) from baseline.
The null hypothesis is that there is no difference in
changes in CBF from baseline between the three inter-
vention arms (low dose, intermediary dose, and pla-
cebo). Based on a type 1 error risk of 5%, a type 2
error risk of 20% (a power of 80%), a standard devi-
ation of 35%, and the possibility to detect or reject a
20% difference between the intervention groups, at
least 25 patients per intervention arm will need to be
randomized.Stratification and design variables
No stratification will take place. Pre-defined design vari-
ables allowing for an adjusted analysis of the primary
outcome and pre-defined subgroup analyses are: age,
sex, Fisher grade, and World Federation of Neurologic
Surgeons grade (WFNS).Figure 1 CONSORT flow chart.Outcome measures
Primary outcome
The primary outcome is changes from baseline in global
CBF, measured by computed tomography perfusion (CT
perfusion) in six representative areas in the brain: the ar-
terial territories of the anterior, middle, and posterior
cerebral arteries in both hemispheres.Secondary outcomes
The secondary outcomes are: 1) occurrence of one or
more DIND during the intervention (Day 5 to 10, where
ictus is Day 0), 2) cerebral vasospasm qualified as severe,
moderate, mild, or absent on a CT angiography, 3)
change from baseline in regional blood flow in each of
the six vascular territories, and 4) Glasgow Outcome
Score (GOS) at three months after SAH.Exploratory outcomes
The exploratory outcomes are: the occurrence of ele-
vated transcranial Doppler values (>50% from baseline)
in the middle cerebral artery and the number of patients
receiving endovascular intervention in the attempt to
treat vasospasm.Adverse events
The following adverse events will be reported: 1) bleed-
ing (any episode of intracranial, intraspinal, intraocular,
intraarticular, pericardial, gastrointestinal, tracheal, oral
cavity, nose, or genital bleeding, or bleeding from inser-
tion sites during the intervention period), 2) infection
(defined as requiring the administration of antibiotic
treatment), and 3) hypotension (>20% drop in mean
Rasmussen et al. Trials 2014, 15:228 Page 3 of 5
http://www.trialsjournal.com/content/15/1/228arterial pressure within one hour after the intervention
is initiated).
Other outcomes: microdialysis and concentration of S100b
Brain microdialysis was planned to be performed on as
many study subjects as possible, however, only a small
number of patients (12 out of 81 as of March 2014) were
monitored with microdialysis due to financial and logis-
tical reasons. The microdialysis data will therefore not
be included in the main analyses, but will instead be
used in a hypothesis-generating post hoc study. Also, the
analysis of S100b and other biomarkers will not be re-




The baseline variables will be as follows: sex, age, co-
morbidities (self-reported or reported by relatives) includ-
ing: hypercholesterolemia, arterial hypertension, previous
stroke, diabetes mellitus, and malignancy, and data on ad-
mission including: WFNS grade, Fisher grade, aneurism
placement, and aneurism treatment mode (clipping or
coiling).
Measurement of outcome variables
A CT perfusion scan will be performed at baseline (Day
2 to 4) and during the intervention (Day 7 to 9). The
analysis of the CT perfusion data will be performed by
two independent evaluators according to the principles
described in the Appendix. The CBF values used in the
final analysis will be the average of these two values,
however consensus reading will be performed for dis-
cordant results (above 20%). A CT angiography will be
performed during the intervention (Day 7 to 9).
All patients will be monitored in the ICU and an as-
sessment of neurological performance will be performed
every four hours by the nursing staff. On the basis of
these observations, the occurrence of DIND as defined
by Vergouwen et al. [5] will be qualified as present or ab-
sent daily by principal investigator. Transcranial Doppler
ultrasonography will be performed daily and any occur-
rence of elevated values (>50 from baseline) will be re-
corded by principal investigator.
General analysis principles
All analyses and interpretations of these outcome vari-
ables will be performed while preserving the blinding of
the statistician and investigators for the interventions.
Abstracts presenting the conclusions will be written and
approved by the investigators before the blinding is
unmasked. Analyses will be conducted according to the
modified intention-to-treat principle [6]. All tests of sig-
nificance will be two-sided with a maximal type-1 errorrisk of 5%. The primary analyses of primary and secondary
outcomes will be those of the modified intention-to-treat
population without adjustment for baseline covariates
and, if necessary, with data sets generated using multiple
imputations.
If there is less than 5% of data missing for a specified
primary or secondary outcome we will perform a com-
plete case analysis without imputing the missing values.
If there is more than 5% of data missing we will perform
Little’s test. If Little’s test indicates that the complete
case data set is a random sample we will continue with-
out imputing missing values and analyze the complete
cases. If Little’s test indicates that the data set of
complete cases is not sampled completely at random of
the total data set, we will report the point estimates and
their 95% confidence interval applying a worst and best
case scenario imputation for the missing values. If the
worst and best case analyses allow for the same conclu-
sion we will not perform multiple imputations. However,
if the worst and best case imputations provide different
conclusions, multiple imputations will be performed,
creating 10 imputed data sets under the assumption of
data missing at random. The result of the trial will be
the pooled intervention effect and 95% CI of the ana-
lyses of each data set after multiple imputation.
Multiplicity, a possibly reason for spurious statistically
significant P values, may be a problem when the result
of several outcomes is presented. Addressing this prob-
lem is important, but we consider adjustment with Bon-
ferroni correction to be too conservative. For the
secondary outcomes we have chosen to consider a P
value below 0.01 as definitely statistical, whereas a P
value between 0.01 and 0.05 will be considered indica-




The flow of study participants will be displayed in a
CONSORT diagram as shown in Figure 1 [7]. The num-
ber of screened patients who fulfil the study inclusion
criteria and the number included in the primary and sec-
ondary analyses as well as all reasons for exclusions in
the primary and secondary analyses will be reported.
Primary outcome
CBF is measured by a CT perfusion scan, covering a 4-
cm slab of the brain at the level of the basal ganglia. For
each patient, six predefined regions of interest (ROIs)
will be identified, each being representative of the arter-
ial territory of the anterior, middle, and posterior cere-
bral artery in both hemispheres.
The continuous outcome of changes in global CBF will
be calculated as follows: the CBF value in each ROI is
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at baseline and the mean of these six differences is then
calculated for each patient. The differences in the means
of this value between the three intervention groups will be
compared using one-way analysis of variance (ANOVA).
Secondary outcomes including adverse events
Frequencies and percentages per group will be reported
with 95% CI. A standard Chi2-test will be used to assess
the effect of treatment on binary and categorical out-
comes (GOS angiographic vasospasm, increased Doppler
values, and occurrence of DIND).
No significance testing will be reported on the individ-
ual sub-scores of GOS and the degree of vasospasm.
GOS will be dichotomized to grade 1 to 4 (death to
moderate disability) and 5 (good outcome). Vasospasm
will be dichotomized to none or mild and moderate or
severe.
Changes in regional blood flow in each of the six vas-
cular territories will be compared for each intervention
group using multiple test of analysis of co-variance
(ANCOVA). For adverse events we will perform a Chi2-
test on patients having one or more adverse events ver-
sus patients having no adverse events.
Outline of figures and tables
Figure one will be a CONSORT flow chart. Figure two will
be a bar chart with confidence intervals displaying the
mean difference in global cerebral perfusion in the three
intervention groups. Figure three will be a bar chart with
confidence intervals displaying occurrences of angio-
graphic vasospasm in the three intervention groups.
All tables will report variables according to randomiza-
tion groups. Table one will report background variables.
Table two will report occurrences of DIND. Table three
will report occurrences of high velocity Doppler values.
Table four will report changes in regional blood flow.
Table five will report adverse events. Table six will report
endovascular interventions. Table seven will report out-
comes for mortality and morbidity at three months with
GOS.
Discussion
The primary outcome described in this statistical plan
has been altered slightly compared with the primary out-
come described in our study protocol [4]. Originally, we
intended to focus exclusively on ROIs with hypoperfu-
sion as these are the most interesting areas regarding
the risk of ischemia and development of brain damage.
However, a pilot analysis of the CT perfusion data on
patients with subarachnoid haemorrhage, performed by
our group, has revealed a risk of systematic overesti-
mation of CBF. Other investigators have also addressed
problems with precise estimation of absolute CBF values[8,9], although CBF quantification by CT perfusion has
been validated [10]. Systematic overestimation of CBF
could result in ROIs being discarded as unimportant
even if there is a large decrease in CBF from baseline.
To allow for an unbiased analysis including all ROIs,
and to minimize the impact of possible overestimation,
we have decided a priori to modify the primary outcome
as described above before the database is accessed.
Trial status
Recruitment started in October 2011 and is currently
ongoing.
Appendix
Analysis of CT perfusion data will be made according to
the following principles:
 All analyses of ROIs will be performed on a Philips
EBW v. 4.5 PC using the software package ‘brain
perfusion’ (Philips Healthcare, P.O. Box 10.000,
5680 DA Best, The Netherlands).
 Mask settings will be <15 HU and >400 HU to
exclude bone and cerebrospinal fluid from the
analysis.
 Vessels in all ROIs will be removed by the software
by checking the ‘remove vessels’ option.
 When selecting the reference artery, the ‘time to
peak’ for all main arteries will be calculated. The
artery that peaks first will be selected as reference.
 When selecting the reference vein, the vein with
the highest net enhancement will be selected.
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